Scholarlink

<p>Hemithorax irradiation (HT‑RT) is a cornerstone multimodal treatment for high‑risk chest wall bone and soft tissue sarcomas, particularly Ewing sarcoma in children and young adults. Current non‑randomized evidence consistently shows HT‑RT reduces systemic relapse—especially lung metastases—without compromising local control or causing unmanageable acute toxicities, and modern techniques (IMRT, VMAT, proton therapy) further improve its therapeutic ratio by lowering late toxicity. Major gaps remain: no prospective randomized controlled trials (RCTs) confirm independent efficacy, the biological mechanisms are unclear, and long‑term pulmonary function and survivorship data in children are insufficient. Future research must prioritize prospective RCTs, pediatric‑specific dose constraints, advanced technique validation, and mechanistic studies to refine patient selection and optimize outcomes for this high‑risk population. Clinical Trial Number: Not applicable.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Hemithorax Irradiation for High-Risk Chest Wall Sarcomas: Current Evidence, Clinical Practice and Future Directions

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月20日

查看全文
  • YuanYou Yang,
  • Xin Sun,
  • Jie Xu,
  • Lu Xie,
  • Gang Ren

摘要

Hemithorax irradiation (HT‑RT) is a cornerstone multimodal treatment for high‑risk chest wall bone and soft tissue sarcomas, particularly Ewing sarcoma in children and young adults. Current non‑randomized evidence consistently shows HT‑RT reduces systemic relapse—especially lung metastases—without compromising local control or causing unmanageable acute toxicities, and modern techniques (IMRT, VMAT, proton therapy) further improve its therapeutic ratio by lowering late toxicity. Major gaps remain: no prospective randomized controlled trials (RCTs) confirm independent efficacy, the biological mechanisms are unclear, and long‑term pulmonary function and survivorship data in children are insufficient. Future research must prioritize prospective RCTs, pediatric‑specific dose constraints, advanced technique validation, and mechanistic studies to refine patient selection and optimize outcomes for this high‑risk population. Clinical Trial Number: Not applicable.